zbbesxzabtudwtxbrvfqbuuceuatc
  • Agenda
    • Programs
    • Symposia
    • Breakout Discussions
    • Short Courses
    • Plenary Keynotes
    • Speaker Biographies
    • Training Seminars
    • Attendees
    • About
    • Archives
  • Sponsor/Exhibitor
    • Attendee Demographics + Event Features
    • Sponsorship Opportunities
    • Current Sponsors
    • Current Exhibitors/Floorplan
    • Exhibit Contract
    • Exhibit Services Schedule
    • Exhibitor Prospectus
    • Lead Generation Opportunities
    • FAQs
  • Downloads
    • Downloads
    • Interviews
    • Podcasts
  • Travel
  • Posters
  • Press
  • Register
    • Commercial Registration
    • Academic Registration
    • Student Fellowship
    • Registration Offerings
sponsorship-exhibit-banner
Demographics Sponsors Opportunities Exhibits Lead Gen FAQ

Sponsors

Premier Sponsor

Corporate Sponsors

  • Cellecta
  • CDD
  • Domainex
  • eurofins
  • Integral
  • Isogenica
  • Reaction Bio
  • Schrodinger

Corporate Support Sponsors

  • Antibody_Solutions
  • Enamine
  • Oxford-Genetics

Outlook YouTube Facebook LinkedIn Twitter
#BostonDOT18

cta-prelim-agenda
View All Sponsors
View Media Partners
DOT Target Stats

September 26-27

  • Small Molecules for Cancer Immunotherapy
  • NK Cell-Based Cancer Immunotherapy

September 27-28

  • Autoimmune and Inflammation Drug Targets
  • Targeting Tumor Myeloid Cells

September 26-27

  • Targeting the Ubiquitin-Proteasome System
  • CNS and Neurodegenerative Targets
  • Constrained Peptides and Macrocyclics
  • Target Identification & Validation – Part 1

September 27-28

  • Kinase Inhibitor Discovery
  • GPCR-Based Drug Discovery
  • Lead Generation Strategies
  • Target Identification & Validation – Part 2

September 26-27

  • Antibacterial Discovery and Development
  • NASH and Fibrosis

September 27-28

  • Targeting Gram-Negative Pathogens
  • Targeting the Microbiome

September 26-27

  • Antibody Discovery Forum – Part 1
  • Antibodies Against Membrane Protein Targets – Part 1

September 27-28

  • Antibody Discovery Forum – Part 2
  • Antibodies Against Membrane Protein Targets – Part 2
  • Antivirals: Targeting HBV and Beyond
  • Targeting Autophagy
  • Regenerative Medicine

September 26-27

  • Machine Learning for Effective Drug Discovery Decisions

September 27-28

  • Introduction to Small Molecule Drug Discovery and Development

CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Genomics

Healthcare

IT & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers

Request Information

Privacy Policy